Research programme: protein-arginine deiminase inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: protein-arginine deiminase inhibitors - Bristol-Myers Squibb

Alternative Names: PAD inhibitors - Bristol-Myers Squibb

Latest Information Update: 07 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; Padlock Therapeutics
  • Developer Bristol-Myers Squibb; Evotec AG
  • Class
  • Mechanism of Action Protein-arginine deiminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 01 Apr 2016 Padlock Therapeutics has been acquired by and merged into Bristol-Myers Squibb
  • 28 May 2015 Padlock Therapeutics in-licenses intellectual property, compounds, assays, data and crystal structures from GlaxoSmithKline
  • 09 Apr 2015 Padlock Therapeutics collaborates with The Scripps Research Institute, National Institutes of Health and University of Massachusetts Medical School for preclinical studies of PAD inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top